Canon U.S.A. announced Thursday it has made a strategic investment in Ottawa-based Spartan Bioscience Inc. to fund research and development of new diagnostic testing products.
Canon’s wholly-owned subsidiary, Canon BioMedical Inc. is looking into ways it can work with Spartan on other products like rapid genetic testing.
“We are excited to continue our efforts as we move into new markets for rapid genetic testing,” Spartan CEO Paul Lem said in a statement. “Working with Canon will help accelerate our progress in the future.”
(Sponsored)
Preparation is key to preventing legal consequences for dismissal, according to Emond Harnden LLP
Companies contending with the difficult process of dismissing an employee must be very careful about their actions, or face potentially serious legal consequences. Being proactive about maintaining accurate and detailed
How The Ottawa Hospital uses AI tools to boost health outcomes and streamline clinical efficiency
Dr. Douglas Manuel says it all began with the Ottawa Ankle Rules algorithm, a set of clinical guidelines developed in the early 1990s by The Ottawa Hospital’s Dr. Ian Stiell
Seymour Liebman, who currently sits on Canon BioMedical’s board of directors will also join Spartan’s board.
“Spartan’s goals align with our mission to provide enhanced diagnostic testing systems that can help improve human health worldwide,” Mr. Liebman said in a statement.
Terms of the investment were not disclosed.
